» Articles » PMID: 39813216

Modeling of Chemo-radiotherapy Targeting Growing Vascular Tumors: A Continuum-level Approach

Overview
Journal PLoS One
Date 2025 Jan 15
PMID 39813216
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study is to demonstrate the enhanced efficiency of combined therapeutic strategies for the treatment of growing tumors, based on computational experiments of a continuous-level modeling framework. In particular, the tumor growth is simulated within a host tissue and treated as a multiphase fluid, with each cellular species considered as a distinct fluid phase. Our model integrates the impact of chemical species on tumor dynamics, and we model -through reaction-diffusion equations- the spatio-temporal evolution of oxygen, vascular endothelial growth factor (VEGF) and chemotherapeutic agents. Simulations of a growing tumor exposed to external radiation showcase the rapid impact of radiotherapy on tumor suppression, however this effect diminishes over time. To enhance the therapeutic efficiency of radiotherapy, we investigate the combination of external radiation with the anti-VEGF drug bevacizumab and the cytotoxic drug docetaxel. Our simulations demonstrate that this synergistic approach integrates the immediate effectiveness of radiation therapy with the enduring tumor-suppressive capabilities of chemotherapy.

References
1.
Lee J, Chung M . Prostate only radiotherapy using external beam radiotherapy: A clinician's perspective. World J Clin Cases. 2022; 10(29):10428-10434. PMC: 9602254. DOI: 10.12998/wjcc.v10.i29.10428. View

2.
Kutuva A, Caudell J, Yamoah K, Enderling H, Zahid M . Mathematical modeling of radiotherapy: impact of model selection on estimating minimum radiation dose for tumor control. Front Oncol. 2023; 13:1130966. PMC: 10600389. DOI: 10.3389/fonc.2023.1130966. View

3.
Darland D, DAmore P . Blood vessel maturation: vascular development comes of age. J Clin Invest. 1999; 103(2):157-8. PMC: 407889. DOI: 10.1172/JCI6127. View

4.
Bissery M, Nohynek G, Sanderink G, Lavelle F . Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs. 1995; 6(3):339-55, 363-8. DOI: 10.1097/00001813-199506000-00001. View

5.
Kenmotsu H, Tanigawara Y . Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose. Cancer Sci. 2015; 106(5):497-504. PMC: 4452149. DOI: 10.1111/cas.12647. View